United States Antibody Discovery Market Insight
Published: 27 May 2026 | Report Format: Electronic (PDF)
The United States antibody discovery market is projected to expand at a CAGR of approximately 9.18% through 2035, driven by increasing investments in biologics research, rising prevalence of chronic and autoimmune diseases, and growing demand for precision medicine and targeted therapeutic development across the pharmaceutical and biotechnology industries.
U.S. Antibody Discovery Market Insights Forecasts to 2035
- The US Antibody Discovery Market Size Was Estimated at USD 4.86 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 9.18% from 2025 to 2035
- The US Antibody Discovery Market Size is Expected to Reach USD 11.67 Billion by 2035
Notable Insights for U.S. Antibody Discovery Market
- By technology, phage display platforms accounted for nearly 34.7% share of the United States antibody discovery market in 2025.
- The United States government invested more than USD 24.8 Billion between 2024 and 2026 toward biomedical innovation programs, oncology drug discovery initiatives, biotechnology infrastructure development, and advanced immunotherapy research, significantly supporting expansion across the domestic antibody discovery industry.
- According to estimates published by the National Institutes of Health, federal funding for antibody engineering, immunology, and biologics-related research programs increased by approximately 13.2% during 2025, while clinical-stage monoclonal antibody development projects expanded by nearly 15.7% across the United States biotechnology sector.
Download the eBook (ToC)
- Based on assessments linked to the U.S. Food and Drug Administration, biologics and antibody-based therapeutics represented approximately 38% of novel drug approvals in 2025, reinforcing strong commercial demand for advanced antibody discovery and screening technologies.
What Makes Decisions Advisors Research Unique?
- Biopharmaceutical Intelligence and Immunotherapy Market Forecasting
Decisions Advisors delivers specialized healthcare market intelligence through comprehensive evaluation of biologics development trends, monoclonal antibody research pipelines, immunotherapy commercialization strategies, precision medicine innovations, and pharmaceutical R&D investments
- Advanced Biotechnology Research Methodology and Clinical Validation
Our analytical methodology integrates pharmaceutical executive interviews, biotechnology research assessments, FDA regulatory evaluations, clinical trial analysis, healthcare expenditure monitoring, and secondary scientific benchmarking to generate highly accurate market forecasts and strategic business intelligence.
- Antibody Engineering Benchmarking and Competitive Landscape Analysis
The study provides a comprehensive analysis of phage display technologies, hybridoma platforms, single B-cell screening systems, AI-enabled antibody discovery tools, recombinant antibody engineering technologies, and high-throughput biologics screening innovations.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the US Antibody Discovery market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Antibody Discovery Market
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- AbbVie Inc.
- Amgen Inc.
- Bio-Rad Laboratories Inc.
- Merck KGaA
- GenScript Biotech Corporation
- Abcam plc
- Creative Biolabs
- Others
Recent Developments:
- In May 2026, Thermo Fisher Scientific Inc. invested approximately USD 420 Million toward the expansion of biologics research infrastructure and advanced antibody screening technologies across the United States, supporting accelerated monoclonal antibody discovery and therapeutic development programs.
- In October 2025, Danaher Corporation introduced an AI-integrated antibody discovery platform designed to improve biologics screening efficiency and reduce early-stage therapeutic development timelines by approximately 21% across selected pharmaceutical research applications.
Market Segmentation:
United States Antibody Discovery Market, By Technology
- Phage Display
- Hybridoma Technology
- Single B-Cell Technology
- Transgenic Animal Platforms
- AI-Based Discovery Platforms
- Others
United States Antibody Discovery Market, By Application
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Neurology
- Cardiovascular Diseases
- Others
United States Antibody Discovery Market, By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations
- Academic & Research Institutes
Expert Views:
According to biotechnology and healthcare industry analysts, the U.S. antibody discovery market is expected to witness robust long-term growth due to rising investments in biologics development, increasing prevalence of chronic diseases, and expanding adoption of precision immunotherapy technologies. Experts indicate that AI-enabled antibody engineering, next-generation monoclonal antibody screening systems, and advanced biologics manufacturing technologies will remain major strategic priorities for pharmaceutical and biotechnology companies.
Author: Govind and Krishna By Spherical Insights and Consulting